When: $390 close with volume expansion

Then: Prepare to honor $383 stop without hesitation

HOLD at 3-5% position size; tighten stop to 383 with early warning at 390; use next 2-4 weeks as decision window based on Q2 commercial MLR and October CMS Star Ratings data; do not add at current levels

• MACD momentum has not turned bullish: MACD line at negative 5.52, signal line at negative 5.43, histogram at negative 0.09 (essentially flat to zero)
• Declining volume bounce not confirmed accumulation: could be weak-conviction rally into resistance; 3.55 million share session interpretation unconfirmed until price action at 50 SMA
• Forward P/E of 17.87x vs 20-24x historical range is not a free option for multiple expansion; market pricing in MLR normalization already
• Macro headwind: higher-for-longer rate regime with 87 percent odds of zero Fed cuts in 2026 and re-accelerating core PCE
• IRS transfer pricing dispute is multi-year overhang suppressing multiple expansion regardless of timeline; explains why stock trades at 17.9x instead of 22x
• Goodwill balance sheet exposure: 110.5 billion dollars (roughly 35 percent of total assets) vulnerable to impairment if commercial MLR deteriorates
• Tangible book value negative 32.7 billion dollars means equity holders receive nothing in liquidation scenario
• Working capital negative 23 billion dollars; thin margin of safety if commercial claims run unexpectedly high
• Management paused share repurchases in Q4 2025 and Q1 2026; sign of capital conservation rather than confidence
• Dividend yield of 2.34 percent not competitive with risk-free alternatives (money market at 4.5 percent, investment-grade corporates at 5 percent)
• Probability-weighted outcomes favor continued basing or support retest over aggressive analyst's 493-538 dollar target scenario requiring multiple expansion in unfavorable macro
• Beta of 0.63 provides limited downside protection when correlations rise in true risk-off scenarios

→ vs aggressive: MACD analysis is flawed: aggressive analyst conflates 'momentum stopped deteriorating' with 'momentum is improving'; histogram at negative 0.09 has not confirmed reversal; crossovers below zero historically less reliable than above zero

→ vs aggressive: Accumulation interpretation is dangerous: 3.55 million share session equally represents weak-conviction rally into resistance; aggressive analyst's technical report itself calls it 'classic weak-conviction rally into resistance'

→ vs aggressive: Asymmetry framing assumes equal probability across outcomes: probability of successful breakout above 413.50 on declining volume, negative MACD, into macro headwind is meaningfully lower than continued basing or support retest

→ vs aggressive: Tepper/Appaloosa dismissal inappropriate: aggressive analyst cites single Motley Fool opinion piece countering multi-billion-dollar institutional exit; original Tepper thesis same as current recovery pitch so he can be early on structural concern not yet played out

→ vs aggressive: Forward P/E bull case pricing in multiple expansion while dismissing bear case for underlying fundamentals; one-sided thinking not asymmetric thinking

Hold 3-5% position size; add only on confirmed breakout above $413.50 with volume above 5 million shares; do not add at $401; honor stop on daily close below $390 with volume expansion

• Hold at 3-5% portfolio weight with $383 stop is correct framework; current $401 level is unfavorable for adding
• Add 1-2 percentage points only on daily close above $413.50 with volume above 5 million shares (confirmation of breakout)
• Use daily close below $390 with volume expansion as early warning to honor $383 stop; do not average down
• MACD histogram compression from -3.04 to -0.009 indicates selling pressure exhausted, not momentum turned—distinguishes between chop and trend
• Volume of 3.55 million shares on $4 bounce is inconclusive: cannot confirm accumulation vs low-conviction drift without price behavior at 50 SMA ($413.22)
• Accumulation-on-declining-volume thesis is 'hope dressed as analysis' until price confirms at resistance
• Tepper exit is confirming data point, not thesis-defining event; should not override underlying fundamentals
• Realistic base case range is $383-$421; most probable outcomes continue basing in $395-$410
• Aggressive analyst's $493-$538 target is tail scenario requiring simultaneous commercial MLR stabilization, IRS resolution, and macro regime shift
• Conservative analyst overreaches on multiple expansion impossibility in higher-for-longer; defensive names with growing dividends can get bid before Fed pivot
• Dividend yield competitiveness argument dismissed too completely; 2.34% yield with ~10% annual dividend growth competes on total return, not raw yield
• Paused buybacks are prudent countercyclical response to elevated medical costs and stock decline, not a confidence signal
• Goodwill concern is legitimate but years-old, not a new risk justifying more cautious stance
• IRS dispute and unresolved commercial MLR trajectory prevent fresh Buy, but franchise quality supports holding core position
• Higher-for-longer rate environment with 87% odds of no 2026 cuts still leaves 13% odds of cuts; market is forward-looking on eventual pivot
• 2-4 week decision window anchored to Q2 commercial MLR commentary and October CMS Star Ratings catalysts
• Consider partial trim at $413 if price stalls without volume confirmation; take profits into resistance when technical confirmation absent
• UNH appropriate as core defensive healthcare holding: 0.63 beta, $24.3B TTM free cash flow, Berkshire retention support role
• Position size should be part of diversified healthcare allocation, not isolated concentration bet
• Do not anchor on $493-$538 target; anything beyond $421 requires sequence of confirmations unknowable today

→ vs aggressive: Multiple expansion to 22-24x forward earnings requires simultaneous commercial MLR stabilization, IRS dispute resolution path, and macro defensive re-rating—unrealistic as near-term catalyst in current 87% no-cut environment

→ vs aggressive: $493-$538 price target is tail scenario, not base case; not appropriate for position sizing decisions today

→ vs aggressive: MACD near-zero compression indicates selling pressure exhausted, not momentum turned; outcome could be chop, not trend

→ vs aggressive: Accumulation-on-declining-volume interpretation is after-the-fact narrative imposition; 3.55M shares on $4 bounce is low-conviction, not enthusiastic institutional accumulation

→ vs conservative: Multiple expansion is not essentially impossible in higher-for-longer; defensive names with growing dividends and low betas get bid when alternatives (money market funds at 4.5%) could roll off as Fed pivots

→ vs conservative: Dividend yield argument dismissed too completely; 2.34% with ~10% annual growth competes on total return profile, not raw yield comparison to money markets

→ vs conservative: Paused buybacks are prudent countercyclical response, not confidence signal; Berkshire not trimming is more meaningful than UNH not buying stock

→ vs conservative: Goodwill concern is years-old and not new risk; over-weighted relative to current catalysts and technical setup

→ vs conservative: Neither side addresses portfolio context; UNH at 3-5% in diversified healthcare allocation is appropriate regardless of near-term uncertainty